down arrow

Edesa Biotech, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA27966L3065
USD
1.69
-0.04 (-2.31%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.691.77

52 Week

1.554.49
Valuation
Technical
Day's Volume

CASH

31.38 k

Shareholding (Mar 2025)

FII

0.32%

Held by 11 FIIs

DII

98.88%

Held by 1 DIIs

Promoter

0.00%

How big is Edesa Biotech, Inc.?

22-Jun-2025

As of Jun 18, Edesa Biotech, Inc. has a market capitalization of 14.12 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -5.84 million over the latest four quarters. As of Sep 24, the company reported shareholder's funds of 1.98 million and total assets of 3.94 million.

Market Cap: As of Jun 18, Edesa Biotech, Inc. has a market capitalization of 14.12 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Edesa Biotech, Inc. reported net sales of 0.00 million and a net profit of -5.84 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 1.98 million and total assets of 3.94 million.

Read More

What does Edesa Biotech, Inc. do?

22-Jun-2025

Edesa Biotech, Inc. is a micro-cap biopharmaceutical company focused on developing clinical-stage drugs for dermatological and gastrointestinal conditions. As of March 2025, it reported a net profit loss of $2 million and has a market cap of $14.12 million.

Overview: <BR>Edesa Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing clinical-stage drugs for dermatological and gastrointestinal indications, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 14.12 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.89 <BR>Return on Equity: -41.60% <BR>Price to Book: 0.91<BR><BR>Contact Details: <BR>Address: 100 Spy Crt, MARKHAM ON : L3R 5H6 <BR>Tel: 1 905 4751234 <BR>Website: https://www.edesabiotech.com/

Read More

Who are in the management team of Edesa Biotech, Inc.?

22-Jun-2025

As of March 2022, the management team of Edesa Biotech, Inc. includes Independent Chairman Mr. Sean MacDonald, CEO Dr. Pardeep Nijhawan, Directors Mr. Frank Oakes, Dr. Lorin Johnson, Mr. Paul Pay, and Mr. Carlo Sistilli. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Edesa Biotech, Inc. includes the following individuals:<BR><BR>- Mr. Sean MacDonald, who serves as the Independent Chairman of the Board.<BR>- Dr. Pardeep Nijhawan, who is the Chief Executive Officer, Corporate Secretary, and a Director.<BR>- Mr. Frank Oakes, who is a Director.<BR>- Dr. Lorin Johnson, who is an Independent Director.<BR>- Mr. Paul Pay, who is also an Independent Director.<BR>- Mr. Carlo Sistilli, who serves as an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Edesa Biotech, Inc. overvalued or undervalued?

25-Jun-2025

Edesa Biotech, Inc. is currently overvalued and classified as "does not qualify" due to significant financial concerns, with key ratios indicating weak valuation metrics and a 54.34% decline in stock price over the past year compared to a 10.26% gain in the S&P 500.

As of 6 February 2017, the valuation grade for Edesa Biotech, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. Based on the current analysis, the company appears to be overvalued. Key ratios include a price-to-book value of 0.83, an EV to EBIT of 0.16, and an EV to EBITDA of 0.17, all of which suggest that the company's valuation metrics are not supportive of a strong investment case.<BR><BR>In comparison to its peers, Edesa Biotech's valuation is notably weaker, with NanoViricides, Inc. also classified as does not qualify but with a slightly worse EV to EBITDA of -2.0886, while Lisata Therapeutics, Inc. is rated risky with an EV to EBITDA of 0.2364. The negative return trends for Edesa Biotech, particularly a 54.34% decline over the past year compared to a 10.26% gain in the S&P 500, further reinforce the notion that the stock is not positioned favorably in the market.

Read More

Is Edesa Biotech, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Edesa Biotech, Inc. has shifted to a mildly bullish trend, supported by positive indicators like a bullish MACD and RSI, despite mixed signals from Bollinger Bands and underperforming the S&P 500 with a -45.50% return over the past year.

As of 21 August 2025, the technical trend for Edesa Biotech, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish RSI on the monthly timeframe. The daily moving averages also indicate a mildly bullish trend. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly and a bearish monthly outlook. The KST is bullish on the weekly but bearish on the monthly, while the OBV is mildly bullish on the weekly with no trend on the monthly.<BR><BR>In terms of performance, Edesa Biotech has underperformed the S&P 500 over the past year, with a return of -45.50% compared to the S&P's 17.14%, and significantly underperformed over the last 3 and 5 years.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.87

stock-summary
Return on Equity

-45.95%

stock-summary
Price to Book

1.21

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.02%
0%
-31.02%
6 Months
-15.08%
0%
-15.08%
1 Year
-30.74%
0%
-30.74%
2 Years
-51.01%
0%
-51.01%
3 Years
72.43%
0%
72.43%
4 Years
-95.49%
0%
-95.49%
5 Years
-95.17%
0%
-95.17%

Edesa Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Edesa Biotech, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Edesa Biotech, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish RSI on the monthly timeframe. The daily moving averages also indicate a mildly bullish trend. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly and a bearish monthly outlook. The KST is bullish on the weekly but bearish on the monthly, while the OBV is mildly bullish on the weekly with no trend on the monthly. In terms of performance, Edesa Biotech has underperformed the S&P 500 over the past year, with a return of -45.50% compared to the S&P's 17.14%, and significantly underperformed over the last 3 and 5 years....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-11.27%
EBIT Growth (5y)
-1.28%
EBIT to Interest (avg)
-11.77
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.89
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
42.83%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.83
EV to EBIT
0.16
EV to EBITDA
0.17
EV to Capital Employed
-0.64
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-41.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.8%)

Foreign Institutions

Held by 11 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 15.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-1.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 26.19% vs 52.00% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-9.00",
          "chgp": "24.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.70",
          "val2": "0.60",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-8.40",
          "chgp": "26.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.90
-1.90
Interest
0.00
0.00
Exceptional Items
0.20
0.20
Consolidate Net Profit
-1.70
-1.70
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.00% vs 15.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Sep'24stock-summary
Sep'24
Sep'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.80
-9.00
24.44%
Interest
0.00
0.00
Exceptional Items
0.70
0.60
16.67%
Consolidate Net Profit
-6.20
-8.40
26.19%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 26.19% vs 52.00% in Sep 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Edesa Biotech, Inc. stock-summary
stock-summary
Edesa Biotech, Inc.
Pharmaceuticals & Biotechnology
Edesa Biotech Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing clinical-stage drugs for dermatological and gastrointestinal indications. Its lead product candidate, EB01, is an sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD). Its pipeline also includes EB02 and EB04. EB02, an sPLA2 inhibitor, is being developed as a treatment for patients with hemorrhoids disease (HD). EB04 is being developed for anal fissures. It is also focused on developing biologic drug candidates for therapeutic, prophylactic and diagnostic applications.
Company Coordinates stock-summary
Company Details
100 Spy Crt , MARKHAM ON : L3R 5H6
stock-summary
Tel: 1 905 4751234
stock-summary
https://www.edesabiotech.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."